Clinicopathological Profiles Associated with Discordant

RAS anti-EGFR therapy colorectal cancer ctDNA liquid biopsy mCRC metastatic colorectal cancer

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
12 Jul 2023
Historique:
received: 06 06 2023
revised: 02 07 2023
accepted: 03 07 2023
medline: 29 7 2023
pubmed: 29 7 2023
entrez: 29 7 2023
Statut: epublish

Résumé

We aimed to identify common mCRC profiles associated with a discordant mutational status of

Identifiants

pubmed: 37509239
pii: cancers15143578
doi: 10.3390/cancers15143578
pmc: PMC10377339
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

Cancers (Basel). 2019 Oct 08;11(10):
pubmed: 31597339
Lancet. 2019 Oct 19;394(10207):1467-1480
pubmed: 31631858
Eur J Cancer. 2018 Nov;103:356-387
pubmed: 30100160
Clin Cancer Res. 2017 Sep 15;23(18):5416-5425
pubmed: 28576867
Clin Adv Hematol Oncol. 2017 Jan;15(1):22-24
pubmed: 28212365
JCO Precis Oncol. 2022 Apr;6:e2100535
pubmed: 35544728
Gut. 2017 Apr;66(4):683-691
pubmed: 26818619
Nat Med. 2023 Jan;29(1):127-134
pubmed: 36646802
Mol Oncol. 2017 Feb;11(2):208-219
pubmed: 28106345
J Clin Oncol. 2023 Jan 20;41(3):678-700
pubmed: 36252154
Clin Cancer Res. 2021 May 1;27(9):2505-2514
pubmed: 33547199
CA Cancer J Clin. 2023 Jan;73(1):17-48
pubmed: 36633525
Ann Oncol. 2016 Aug;27(8):1386-422
pubmed: 27380959
Front Oncol. 2020 Jul 16;10:1115
pubmed: 32766143
Gut. 2022 Jul;71(7):1340-1349
pubmed: 34489309
Ann Oncol. 2017 Jun 01;28(6):1294-1301
pubmed: 28368441
J Mol Diagn. 2017 Mar;19(2):183-186
pubmed: 28190460
Ann Oncol. 2023 Jan;34(1):111-120
pubmed: 36208697
Curr Colorectal Cancer Rep. 2019 Apr;15(2):61-69
pubmed: 31130830
Trends Mol Med. 2020 May;26(5):519-528
pubmed: 32359482
Br J Cancer. 2018 Dec;119(12):1464-1470
pubmed: 30467411
Ann Oncol. 2017 Aug 01;28(8):1713-1729
pubmed: 28407110
Eur J Cancer. 2017 Apr;75:3-4
pubmed: 28214423
Ann Oncol. 2018 May 1;29(5):1211-1219
pubmed: 29438522
Sci Rep. 2016 Jul 15;6:29765
pubmed: 27416752
Ann Oncol. 2022 Aug;33(8):750-768
pubmed: 35809752
Ann Oncol. 2014 Jul;25(7):1346-1355
pubmed: 24718886
PLoS One. 2020 Jul 2;15(7):e0235623
pubmed: 32614932
N Engl J Med. 2022 Jun 16;386(24):2330-2331
pubmed: 35657319
Ann Oncol. 2017 Sep 01;28(9):2149-2159
pubmed: 28911069
Ann Oncol. 2011 Jul;22(7):1535-1546
pubmed: 21228335
Int J Cancer. 2021 Sep 15;149(6):1385-1397
pubmed: 33961700
PLoS Med. 2021 May 3;18(5):e1003620
pubmed: 33939694
J Natl Compr Canc Netw. 2021 Mar 02;19(3):329-359
pubmed: 33724754
Nat Commun. 2019 Aug 19;10(1):3722
pubmed: 31427573
Clin Transl Oncol. 2020 Nov;22(11):1976-1991
pubmed: 32418154
Cancers (Basel). 2021 Nov 17;13(22):
pubmed: 34830904
Science. 2021 Apr 9;372(6538):
pubmed: 33833097
J Clin Oncol. 2011 May 20;29(15):2011-9
pubmed: 21502544
J Oncol Pract. 2017 May;13(5):333-337
pubmed: 28350513
Ann Oncol. 2018 Oct 1;29(Suppl 4):iv192-iv237
pubmed: 30285222
ESMO Open. 2019 Dec 1;4(6):e000599
pubmed: 31803504
Nature. 2012 Jun 28;486(7404):532-6
pubmed: 22722830
Ann Oncol. 2023 Jan;34(1):10-32
pubmed: 36307056
J Clin Oncol. 2011 Nov 20;29(33):4401-9
pubmed: 21969498
Br J Cancer. 2019 May;120(10):982-986
pubmed: 31015557
Front Oncol. 2020 Jun 16;10:964
pubmed: 32612957
CA Cancer J Clin. 2020 Nov;70(6):443-459
pubmed: 32940362
Clin Cancer Res. 2021 May 1;27(9):2515-2522
pubmed: 33602686
Ann Oncol. 2017 Jun 01;28(6):1325-1332
pubmed: 28419195
Ann Oncol. 2017 Dec 1;28(12):2943-2949
pubmed: 28945877
Cancer Cell. 2018 Jan 8;33(1):125-136.e3
pubmed: 29316426
CA Cancer J Clin. 2020 May;70(3):145-164
pubmed: 32133645
JAMA Oncol. 2017 Feb 01;3(2):194-201
pubmed: 27722750
Clin Transl Oncol. 2019 Jan;21(1):46-54
pubmed: 30565083

Auteurs

Elena Brozos-Vázquez (E)

Translational Medical Oncology Group, Oncomet, University Hospital of Santiago de Compostela (CHUS), 15706 Santiago de Compostela, Spain.

Ramón Manuel Lago-Lestón (RM)

Translational Medical Oncology Group, Oncomet, University Hospital of Santiago de Compostela (CHUS), 15706 Santiago de Compostela, Spain.
Liquid Biopsy Unit, Health Research Institute of Santiago de Compostela (IDIS), 15706 Santiago de Compostela, Spain.

Marta Covela (M)

Department of Medical Oncology, Lucus Augusti University Hospital of Lugo (CHULA), 27003 Lugo, Spain.

Juan de la Cámara Gómez (J)

Department of Medical Oncology, University Hospital of Ferrol (CHUF), 15405 Ferrol, Spain.

Ana Fernández-Montes (A)

Department of Medical Oncology, University Hospital Complex of Ourense (CHUO), 32005 Ourense, Spain.

Sonia Candamio (S)

Translational Medical Oncology Group, Oncomet, University Hospital of Santiago de Compostela (CHUS), 15706 Santiago de Compostela, Spain.

Yolanda Vidal (Y)

Translational Medical Oncology Group, Oncomet, University Hospital of Santiago de Compostela (CHUS), 15706 Santiago de Compostela, Spain.

Francisca Vázquez (F)

Translational Medical Oncology Group, Oncomet, University Hospital of Santiago de Compostela (CHUS), 15706 Santiago de Compostela, Spain.

Alicia Abalo (A)

Translational Medical Oncology Group, Oncomet, University Hospital of Santiago de Compostela (CHUS), 15706 Santiago de Compostela, Spain.
Liquid Biopsy Unit, Health Research Institute of Santiago de Compostela (IDIS), 15706 Santiago de Compostela, Spain.

Rosa López (R)

Translational Medical Oncology Group, Oncomet, University Hospital of Santiago de Compostela (CHUS), 15706 Santiago de Compostela, Spain.

Cristina Blanco (C)

Translational Medical Oncology Group, Oncomet, University Hospital of Santiago de Compostela (CHUS), 15706 Santiago de Compostela, Spain.

Laura Muinelo-Romay (L)

Translational Medical Oncology Group, Oncomet, University Hospital of Santiago de Compostela (CHUS), 15706 Santiago de Compostela, Spain.
Liquid Biopsy Unit, Health Research Institute of Santiago de Compostela (IDIS), 15706 Santiago de Compostela, Spain.
Centro de Investigación Biomédica en Red Cáncer (CIBERONC), 28029 Madrid, Spain.

Isabel Ferreirós-Vidal (I)

Translational Medical Oncology Group, Oncomet, University Hospital of Santiago de Compostela (CHUS), 15706 Santiago de Compostela, Spain.
Liquid Biopsy Unit, Health Research Institute of Santiago de Compostela (IDIS), 15706 Santiago de Compostela, Spain.

Rafael López-López (R)

Translational Medical Oncology Group, Oncomet, University Hospital of Santiago de Compostela (CHUS), 15706 Santiago de Compostela, Spain.
Liquid Biopsy Unit, Health Research Institute of Santiago de Compostela (IDIS), 15706 Santiago de Compostela, Spain.
Centro de Investigación Biomédica en Red Cáncer (CIBERONC), 28029 Madrid, Spain.

Classifications MeSH